Nektar Therapeutics has grown revenue −15% a year over three years and −12% a year over five. Revenue growth, 3-year annual rate: −15% (Biotechnology median +17%). Revenue growth, 5-year rate: −12%, growth has slowed since the five-year average. Years of annual history on file: 17, FY2009 to FY2025, as filed.

NKTRNektar Therapeutics

Healthcare

$41.14-25% 1Y

$41.14

$35.1252 weeks$100.35

Is it growing?

Watch

Growth is fading: revenue shrinking (−27% year on year) and operating margin narrowing (−82.5 points).

2 to watch, 1 without data

Revenue trend−27% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −12% a year.

Margin direction−82.5 points operating

Trailing-twelve-month operating margin, -293.3% now against -210.8% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NKTR growing?

Nektar Therapeutics has grown revenue −15% a year over three years and −12% a year over five.

−15%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −12%
Revenue growth, 5-year rate · −15% over three · growth has slowed since the five-year average
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed

Details›